Related Experiment Video
Updated: Sep 12, 2025
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients
Tiantian Zhang1,2,3, Aixue Zhang4,5, Jing Li6
1College of Pharmacy, Jinan University, Guangzhou, China.
Objectives:
To compare the measurement properties between EQ-5D-5L/SF-6Dv2 and QLU-C10D utilities, and to assess the implications of their adoption in QALY estimation in hematologic cancer patients.
Method:
Longitudinal data of Chinese lymphoma and myeloma patients were adopted. Utility scores of the three instruments were calculated based on a variety of country-specific value sets. Their measurement properties including convergent validity, known-group validity, sensitivity, and responsiveness were compared. With-in group change in utilities derived from the instruments were also generated and compared.
Results:
A total of 200 lymphoma and 139 myeloma patients were enrolled at baseline; and 78 and 89 of them were followed up, respectively. The three kinds of utilities showed similar convergent validity; but all had restricted known-group validity. All of them could identify meaningful changes in clinical status; while whether QLU-C10D utilities was more responsive and yielded larger utility change were closely related to the value sets adopted.
Conclusion:
It appears that the advantages of QLU-C10D over EQ-5D-5L/SF-6Dv2 were not so obvious, and it may not necessarily produce more QALY gains as well. The choice of utility value set played an important role in the two aspects.
